Topics

CAR-T and Gynecologic Cancers

Cancer Immunotherapy Tumor Microenvironment Cellular Stress Cell Programmed Death

Gynecologic cancers are attractive candidates for CAR-T therapy because recurrent ovarian, cervical, and endometrial tumors often have limited curative options and can express accessible surface antigens. Engineered T-cell programs have investigated MUC16, mesothelin, folate receptor alpha, HER2, and other targets, while conventional adoptive cell therapy has provided broader evidence that transferred lymphocytes can act against these malignancies. Clinical development remains early compared with hematologic CAR-T therapy. Most gynecologic tumors are solid, antigen expression is uneven, and several candidate proteins are also present on healthy tissue. The central task is therefore not simply to produce a reactive CAR, but to create a cell product that discriminates tumor, reaches peritoneal and metastatic disease, and remains functional in an immunosuppressive niche The anatomy of pelvic and peritoneal disease also makes local exposure and compartment-specific immune monitoring unusually relevant[1][2][3].

CAR recognition bypasses major histocompatibility complex presentation by coupling an antibody-derived binding domain to CD3ζ and a costimulatory module. This can be advantageous when tumors downregulate antigen processing, but efficacy still depends on sufficient and stable surface antigen density. Ovarian cancer illustrates the major barriers: ascites and peritoneal implants contain suppressive macrophages, regulatory T cells, inhibitory cytokines, hypoxia, nutrient competition, and checkpoint ligands. Dense stroma and abnormal vasculature impede trafficking, while repeated stimulation promotes exhaustion. Cervical cancers may provide virally derived antigens for T-cell receptor approaches, but CARs require an appropriate surface target. Endometrial tumors are biologically diverse, making molecular subtype and immune context important when selecting a cell-therapy strategy Heterogeneous prior surgery and chemotherapy further influence target availability, inflammatory signaling, and the quality of cells collected for manufacturing[1][3].

Investigational applications include intravenous or intraperitoneal CAR-T delivery, T cells engineered to secrete cytokines, checkpoint-resistant constructs, and combinations with checkpoint inhibitors or agents that remodel stroma and myeloid cells. Regional administration may increase exposure to ovarian cancer deposits while limiting immediate systemic distribution, although it cannot address every metastatic site. Logic-gated and dual-target receptors aim to reduce antigen escape and improve selectivity by requiring a tumor-associated combination rather than one imperfect marker. Safety remains critical because low-level target expression on normal mesothelial, epithelial, or vascular tissues can cause on-target, off-tumor injury. Manufacturing fitness is another variable: heavily pretreated patients may provide T cells with limited proliferative reserve A platform that works in ovarian ascites may not automatically address nodal, hepatic, pulmonary, or central nervous system metastases[1][2].

Future trials should begin with rigorous spatial mapping of target density in primary tumors, metastases, and normal organs. Serial sampling can determine whether treatment failure reflects poor trafficking, antigen loss, or acquired cellular dysfunction. Studies also need standardized reporting of expansion, persistence, cytokine toxicity, and compartment-specific response, particularly for peritoneal disease. Patient-derived organoids, explants, and immune-competent models can test recognition thresholds before clinical exposure. Combining CAR-T cells with vaccination, oncolytic viruses, antiangiogenic therapy, or localized cytokine delivery may be valuable only when a measured barrier justifies the partner. CAR-T therapy has credible potential in gynecologic cancer, but durable benefit will require tumor-selective antigen logic, regional and systemic control, and engineered resistance to the local microenvironment Success should therefore be judged by durable multisite control, not by transient clearance of a single antigen-rich lesion[1][2][3].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-50895 Gefitinib
Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer .
EGFR   Autophagy   Apoptosis  
Colorectal Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Lipid Metabolism   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Metastatic Breast Cancer   SARS-CoV-2 Infection  
222
HY-15772 Osimertinib
Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
EGFR  
Lung Cancer   Colorectal Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Glucose Metabolism   SARS-CoV-2 Infection   Hepatitis C Virus Infection   Obesity  
208
HY-50896 Erlotinib
Erlotinib (CP-358774) is a selective, orally active EGFR tyrosine kinase inhibitor. Erlotinib also acts as a substrate and inhibitor of OATP2B1, with an IC50 of approximately 0.079 μM for inhibiting OATP2B1-mediated uptake of estrone 3-sulfate. Erlotinib blocks EGFR phosphorylation, downstream signal transduction, as well as the growth and proliferation of cancer cells. Erlotinib inhibits MMP-10-mediated renal injury, fibrotic lesions, the ERK1/2, GSK-3β and β-catenin signaling pathways, fibronectin, α-SMA, collagen deposition, and renal injury markers. Erlotinib is metabolized via CYP3A to produce the active metabolite OSI-420. Erlotinib can be used in research related to non-small cell lung cancer, gastric cancer, papillary renal cell carcinoma, pancreatic cancer, renal fibrosis, and other conditions.
EGFR   OAT   ERK   GSK-3   β-catenin  
Gastric Cancer   Pancreatic Cancer   Renal Disease   Non-Small Cell Lung Cancer   Lung Adenocarcinoma  
147
HY-10261 Afatinib
Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer.
EGFR   Autophagy   Apoptosis   c-Met/HGFR   Akt   p38 MAPK  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Neurodegenerative Disease   Depression   Pain   Digestive System Inflammation   Hepatitis C Virus Infection   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
113
HY-50898 Lapatinib
Lapatinib (GW572016) is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively.
EGFR   Autophagy   Ferroptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   HER-2 Positive Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection   Hepatitis C Virus Infection   Obesity  
100
HY-14596 Genistein
Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.
EGFR   Autophagy   Apoptosis   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Lung Cancer   Colorectal Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Digestive System Inflammation   SARS-CoV-2 Infection   Hepatitis C Virus Infection   Obesity  
94
HY-L031 Small Molecule Immuno-Oncology Compound Library
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 831 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Disease Focused Libraries

88
HY-L173 Anti-Ovarian Cancer Compound Library
Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer. MCE designs a unique collection of 2,967 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.

Disease Focused Libraries

83
HY-16141 Cilengitide
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.
Integrin   TGF-β Receptor   Apoptosis   PD-1/PD-L1   STAT   Akt   mTOR  
Melanoma   Glioblastoma  
75
HY-P9907 Trastuzumab
Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer. (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)

Species: Human

Radionuclide-Drug Conjugates (RDCs)   EGFR   ADC Antibodies  
Non-Small Cell Lung Cancer   Luminal Breast Cancer   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
71
HY-Y1269D Ammonium chloride, for molecular biology
Ammonium chloride (Salmiac), for molecular biology is an inhibitor of Slc26a4 and SMAD2. Ammonium chloride, for molecular biology reduces the protein expression level of Slc26a4 in lung tissue, and attenuates ozone-induced increases in proinflammatory cytokines, inflammatory cells, pulmonary resistance, goblet cell hyperplasia, peribronchial inflammation and thiocyanate levels in mouse tissues and bronchoalveolar lavage fluid. Ammonium chloride, for molecular biology decreases the level of phosphorylated SMAD2, inhibits autophagy by reducing autophagy-related proteins, and enhances Cisplatin (HY-17394)-induced cancer cell apoptosis and DNA double-strand breaks. Ammonium chloride, for molecular biology also inhibits the TCA cycle, reduces ATP production, increases glucose utilization, regulates the levels of lactic acid, glutamic acid and ATP, and induces morphological degeneration of neuroblastoma cells. Ammonium chloride, for molecular biology can be used in studies related to ozone-induced airway injury, hepatocellular carcinoma, human cervical cancer, hepatic encephalopathy, Reye syndrome, epilepsy and neurodegenerative diseases.
TGF-beta/Smad   Apoptosis   Chloride Channel  
Cancer   Epilepsy  
62
HY-P9905 Cetuximab
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity.

Species: Human

Radionuclide-Drug Conjugates (RDCs)   EGFR  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
57
HY-P9904 Atezolizumab
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Species: Human

PD-1/PD-L1   Apoptosis   Autophagy  
Colorectal Cancer   Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
42
HY-P9902 Pembrolizumab
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
37
HY-19991 BMS-1
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
PD-1/PD-L1   Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
34
HY-19745 BMS-202
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.
PD-1/PD-L1   Apoptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
27
HY-P99144 Anti-Mouse PD-1 Antibody (RMP1-14)
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.

Species: Mouse

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
27
HY-N0519 Calycosin
Calycosin is a compound that can be isolated from Radix Astragali. Calycosin has strong antioxidant, anti-inflammatory and apoptosis-modulating effects. Calycosin can be used for the research of ovarian cancer and breast cancer.
Apoptosis  
Neurological, Eye or Ear Disease   Digestive System Disease   Breast Cancer   Ovarian Cancer   Digestive System Inflammation  
23
HY-P9903 Nivolumab
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection  
23
HY-P99145 Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer.

Species: Mouse

PD-1/PD-L1  
Colorectal Cancer  
20
HY-138298 Trastuzumab deruxtecan (solution)
Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.
Antibody-Drug Conjugates (ADCs)   EGFR  
Breast Cancer   Gastric Cancer  
12
HY-138298A Trastuzumab deruxtecan
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.
Antibody-Drug Conjugates (ADCs)   EGFR  
Breast Cancer  
12
HY-N0621 Morin
Morin is an orally active plant-derived flavonoid. Morin inhibits ROS generation. Morin induces Apoptosis. Morin inhibits PTP1B (IC50 of 15 μM) and activates the insulin receptor. Morin has a detoxifying effect. Morin can be used in diabetes, leukemia, colon cancer, cervical cancer, Parkinson's disease and hypertension research.
Environmental Pollutants   Phosphatase   Reactive Oxygen Species (ROS)   Insulin Receptor   Apoptosis  
Colorectal Cancer   Leukemia/Lymphoma/Myeloma   Digestive System Inflammation   Cardiovascular Disease   Glucose Metabolism   Parkinson's Disease   Obesity  
10
HY-B0216 Ethinylestradiol
Ethinylestradiol is an orally active steroidal estrogen. Ethinylestradiol is widely used in research on menopausal symptoms, gynecological conditions, and certain hormone-sensitive cancers.
Endogenous Metabolite   Estrogen Receptor/ERR  
Metabolic or Endocrine Disease   Metastatic Breast Cancer   SARS-CoV-2 Infection  
9
HY-P9919 Durvalumab
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.

Species: Human

PD-1/PD-L1  
Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
7
HY-P7696 CA125 Protein, Human (HEK293, His)
CA125 is a giant mucin-like glycoprotein expressed by epithelial ovarian neoplasms and cells, which is an antigenic tumor marker. CA125 provides a protective, lubricating barrier against particles and infectious agents at mucosal surfaces. CA125 binds to mesothelin (MSLN) mediates heterotypic cell adhesion, contributing to the metastasis of ovarian cancer to the peritoneum by initiating cell attachment to the mesothelial epithelium. CA125 is widely used for monitoring with ovarian epithelial cancer. CA125 Protein, Human (HEK293, His) is a recombinant human cancer antigen 125 (CA125) with a His label and is expressed in HEK293 cells.

Species: Human; Source: HEK293

CAR-T Related Proteins CA-125

4
HY-N2072 Crocetin
Crocetin (Transcrocetin) is an aglycone of crocin. Crocetin is an orally active and brain-penetrant. Crocetin shows strong NMDA receptor affinity and channel opening activity. Crocetin can downregulate the proinflammatory cytokines and COX-2 exoression. Crocetin can inhibit apoptosis and activation of MAPK. Crocetin can delay delays brain and body aging. Crocetin can be used for the researches of cancer, neurological disease and inflammation, such as cervical cancer and ischemia.
iGluR   Apoptosis   COX   p38 MAPK  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
3
HY-P99006 Amatuximab
Amatuximab (MORab-009) is a chimeric, humanized IgG1/k MAb that targets the cell surface mesothelin (MSLN). Mesothelin is a glycosylphosphatidyl inositol (GPI)-anchored membrane glycoprotein, which is present in a restricted set of normal adult tissues such as the mesothelium.

Species: Human

Mesothelin  
Pancreatic Cancer   Ovarian Cancer   Non-Small Cell Lung Cancer  
3
HY-13673 Goserelin
Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer.
GnRH Receptor   Apoptosis  
Metabolic or Endocrine Disease   Luminal Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
2
HY-N1511 Ganoderic acid D
Ganoderic acid D, a highly oxygenated tetracyclic triterpenoid, is the major active component of Ganoderma lucidum. Ganoderic acid D upregulates the protein expression of SIRT3 and induces the deacetylated cyclophilin D (CypD) by SIRT3. Ganoderic acid D inhibits the energy reprogramming of colon cancer cells including glucose uptake, lactate production, pyruvate and acetyl-coenzyme production in colon cancer cells. Ganoderic acid D induces HeLa human cervical carcinoma apoptosis.
Sirtuin   Apoptosis  
Colorectal Cancer   Digestive System Inflammation  
2
HY-160109 Ac5GalNTGc
Ac5GalNTGc is a potent, peracetylated C-2 thioglycolyl-substituted GalNAc analog that efficiently inhibits mucin-type O-glycan biosynthesis. Ac5GalNTGc reduces leukocyte sialyl-Lewis-X expression and inhibits L-/P-selectin mediated rolling under flow, as well as P-selectin dependent leukocyte-platelet adhesion. Ac5GalNTGc exhibits anti-inflammatory activity in a thioglycollate-induced acute peritonitis model. Ac5GalNTGc can be used for studies of O-glycan/mucin biology, inflammation, and related translational research.
Mucin  
Inflammation or Immune System Disease  
2
HY-W053583 Tetraxetan
Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., 68Ga, 111In, 177Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .
Biochemical Assay Reagents   Radionuclide-Drug Conjugates (RDCs)  
Cancer  
2
HY-13673A Goserelin acetate
Goserelin acetate (ICI-118630 acetate), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin acetate can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer.
GnRH Receptor   Apoptosis  
Metabolic or Endocrine Disease   Luminal Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
2
HY-N0519R Calycosin (Standard)
Calycosin (Standard) is the analytical standard of Calycosin. This product is intended for research and analytical applications. Calycosin is a compound that can be isolated from Radix Astragali. Calycosin has strong antioxidant, anti-inflammatory and apoptosis-modulating effects. Calycosin can be used for the research of ovarian cancer and breast cancer.
Reference Standards   Apoptosis  
Cancer   Neurological, Eye or Ear Disease  
1
HY-13545 ABT-510
ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD).
Apoptosis  
Cancer   Inflammation or Immune System Disease  
1
HY-10087S Navitoclax-d8
Navitoclax-d8 is the d8-labeled Navitoclax (HY-10087). Navitoclax (ABT-263 ) is an orally active BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w, with a Ki value of <1 nM for each target. Navitoclax triggers endogenous Apoptosis and downregulates the expression of Survivin and TGFβ2. Navitoclax alleviates fibrosis and induces thrombocytopenia. Navitoclax exhibits anticancer activity against a variety of tumors and enhances the efficacy of chemotherapy and radiotherapy. Navitoclax can be used in the research of acute lymphoblastic leukemia, ovarian cancer, and fibrotic diseases.
Isotope-Labeled Compounds   Bcl-2 Family   Apoptosis   Survivin   TGF-β Receptor  
Ovarian Cancer   Triple-Negative Breast Cancer   Acute Lymphoblastic Leukemia   Platelet Disease  
1
HY-P1103 CTCE-9908
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells.
CXCR  
Cancer  
1
HY-13545B ABT-510 acetate
ABT-510 acetate is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 acetate also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 acetate can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD).
Apoptosis  
Cancer   Inflammation or Immune System Disease  
1
HY-NP159 House Dust Mite Extract, from D.farinae
House Dust Mite Extract, from D.farinae is a house dust mite allergen extract derived from Dermatophagoides farinae. House Dust Mite Extract, from D.farinae significantly increases the levels of cytokines (IL-4, IL-5, IL-6) in bronchoalveolar lavage fluid. House Dust Mite Extract, from D.farinae upregulates the overexpression of MUC5AC. House Dust Mite Extract, from D.farinae induces allergic asthma and pulmonary inflammation.
Mucin   Interleukin Related  
Allergic Asthma  
1
HY-P99732 Minretumomab
Minretumomab (CC-49) is a murine monoclonal antibody against TAG-72 (tumor-associated glycoprotein 72). Minretumomab is used in cancer and immunity research.

Species: Human

Mucin  
Cancer  
1
HY-D2452 Cy3-Cisplatin
Cy3-Cisplatin is a Cyanine 3 fluorescent dye CY3 (HY-D0822) labled Cisplatin (HY-17394). Cy3-Cisplatin can be used for drug delivery, fluorescent labeling, cell imaging and tracking.
Fluorescent Dye  
1
HY-P10284 S7
S7 is an inhibitory polypeptide targeting IL-6R, which specifically binds to IL-6R and its A chain (gp80/IL-6RA) to block its signal transduction. S7 inhibits IL-6-mediated anti-apoptosis (apoptosis), angiogenesis and the expression of VEGF-A, blocks related survival signaling pathways, and enhances the sensitivity of cancer cells to chemotherapeutic drugs. S7 can be applied to the research of related diseases such as cervical cancer, multiple myeloma, Kaposi's sarcoma, prostate cancer and basal cell carcinoma.
Interleukin Related   VEGFR   Apoptosis  
Cancer   Heart Failure  
1
HY-125474 Carrageenan
Carrageenan is an antiviral and anticancer agent. Carrageenan inhibits herpes simplex virus (HSV), HIV, and hepatitis A virus (HAV) by directly binding to the viral capsid to block the attachment of viruses such as HPV to HSPG factors on the cell surface. Carrageenan delays and arrests cell cycle progression, exhibits cytotoxicity against HeLa cancer cells, and can be applied to studies related to cervical cancer, genital warts, hepatitis A, and other conditions. Carrageenan also induces acute non-immune inflammation, triggers a three-phase inflammatory response involving the release of multiple proinflammatory mediators, and causes persistent edema, hyperalgesia, and neutrophil recruitment in mice.
Environmental Pollutants   HSV   HIV  
Cervical Cancer   HIV Infection   Hepatitis Virus Infection   HSV Infection  
1
HY-P99117 Cadonilimab
Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC).

Species: Human

PD-1/PD-L1   CTLA-4  
Inflammation or Immune System Disease   Gastric Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-121608 Lumiflavin
Lumiflavin (Lumiflavine), a riboflavine analog, causes significant inhibition of riboflavine uptake. Lumiflavin can effectively reduce the riboflavin enrichment in cancer stem-like cells (CSCs) and sensitize the effect of cisplatin Diamminedichloroplatinum (DDP) on CSCs. Lumiflavin is promising for research of ovarian cancer.
Fluorescent Dye   Notch  
1
HY-P99634 Gatipotuzumab
Gatipotuzumab (PankoMab) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC).

Species: Human

Mucin  
Cancer  
1
HY-P99675 Ivonescimab
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL).

Species: Human

PD-1/PD-L1   VEGFR  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-185561 Misitatug blivedotin
Misitatug blivedotin (RC88) is an antibody-drug conjugate (ADC) targeting mesothelin (MSLN). Misitatug blivedotin binds to mesothelin and exhibits dose‐dependent antitumor activity. Misitatug blivedotin can be used for the research of ovarian cancer, non-squamous non-small-cell lung carcinoma, cervical cancer.
Mesothelin  
Cervical Cancer   Ovarian Cancer   Non-Small Cell Lung Cancer  
/
HY-18719S Endoxifen-d5 (Z-isomer)
Endoxifen-d5 (Z-isomer) is the deuterated-labeled Endoxifen (Z-isomer methanesulfonate) (HY-18719H). Endoxifen-d5 Z-isomer is an orally active selective PKCβ1 inhibitor with an IC50 of 360 nM against human PKCβ1. It also acts as an estrogen receptor modulator and antiestrogen. Endoxifen-d5 Z-isomer binds to and blocks ERα, ERβ and PKCβ1, inhibits estrogen and PI3K/AKT/mTORC1 signaling pathways, suppresses the expression of genes associated with cell cycle, cell proliferation and extracellular matrix remodeling, and induces apoptosis, reactive oxygen species (ROS) production and hypoxic features. Endoxifen-d5 Z-isomer inhibits tumor growth in breast tumor and glioblastoma models, reduces bone turnover and blood lipid levels, and does not require metabolism via CYP2D6. It can be used in research related to ER+ breast cancer, invasive breast cancer, glioblastoma multiforme, type I bipolar disorder, desmoid tumor, gynecological malignancies, melanoma and hormone receptor-positive solid tumors
PKC   Estrogen Receptor/ERR   PI3K   Akt   mTOR   Apoptosis   Reactive Oxygen Species (ROS)  
Breast Cancer   Melanoma   Glioblastoma  
/
HY-P9943 Igovomab
Igovomab is a monoclonal antibody for imaging. Igovomab can be used for ovarian cancer research.

Species: Human

Transmembrane Glycoprotein  
Cancer  
/
HY-B2099S Buformin-d9 hydrochloride
Buformin-d9 (hydrochloride) is the deuterium labeled Buformin. Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al).
Isotope-Labeled Compounds   AMPK  
Metabolic or Endocrine Disease  
/
HY-B1415S Clofibric acid-d4
Clofibric acid-d4 is the deuterium labeled Clofibric acid (HY-B1415). Clofibric acid also is an herbicideClofibric acid (Chlorofibrinic acid) is an orally active PPARα agonist. Clofibric acid inhibits the fimbriation of Escherichia coli. Clofibric acid increases SOD activity. Clofibric acid lowers blood lipids and prevents experimental pyelonephritis. Clofibric acid has anticancer activity against ovarian cancer. Clofibric acid is also a herbicide. Clofibric acid is used in ovarian cancer, liver cancer, obesity, and urinary tract infection research.
Isotope-Labeled Compounds   PPAR   Bacterial   SOD  
Cancer   Metabolic or Endocrine Disease  
/
HY-W1123936D DBCO-PEG3400-FA
DBCO-PEG-FA (DBCO-PEG-Folate) (MW 3400) is a multifunctional bioconjugation reagent, which is a copolymer of DBCO and Folic acid (FA) (HY-16637) and can target folate receptors (FR). Folate receptors are highly overexpressed on the surface of many cancer cells (such as lung cancer, nasopharyngeal cancer, ovarian cancer, etc.), but exhibit extremely low expression levels in normal tissues. DBCO-PEG-FA can be used for click chemistry conjugation via its DBCO terminal, and thus applies to various bioconjugation and drug delivery applications.
Folate Receptor (FR)  
/
HY-P11255 SPDI-48-T1
SPDI-48-T1 is a lysine-stapled peptide. SPDI-48-T1 exhibits discernible binding affinities for MDM2 and MDMX, with Kd values of 396 nM and 456 nM, respectively. SPDI-48-T1 exhibits anticancer activity against breast cancer, colorectal cancer, non-small cell lung cancer, cervical cancer, and malignant melanoma.
MDM-2/p53  
Cancer  
/
HY-W1123936H DBCO-PEG10000-FA
DBCO-PEG10000-FA (DBCO-PEG10000-Folate) is a multifunctional bioconjugation reagent, which is a copolymer of DBCO and Folic acid (FA) (HY-16637) and can target folate receptors (FR). Folate receptors are highly overexpressed on the surface of many cancer cells (such as lung cancer, nasopharyngeal cancer, ovarian cancer, etc.), but exhibit extremely low expression levels in normal tissues. DBCO-PEG-FA can be used for click chemistry conjugation via its DBCO terminal, and thus applies to various bioconjugation and drug delivery applications.
Folate Receptor (FR)  
/
HY-P991292 AB-3A4
AB-3A4 is a human IgG1 monoclonal antibody (mAb) targeting KAAG1. AB-3A4 can be used in the study of ovarian cancer, triple-negative breast cancer, and prostate cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

ADC Antibodies  
Cancer  
/
HY-P992338 CT-1119
CT-1119 is an autologous human anti-Mesothelin chimeric antigen receptor macrophage (CAR-M). CT-1119 mediates CAR-dependent, antigen-dependent functional activities. CT-1119 acts as a phagocytosis inducer, tumor cell killer, pro-inflammatory cytokine inducer, and M1 macrophage polarizer. CT-1119 exhibits stronger resistance to M2 repolarization and reduces tumor burden in a mouse lung cancer xenograft model. CT-1119 can be used for the research of mesothelin-expressing solid tumors.

Species: Human

Mesothelin   Constitutive Androstane Receptor  
Inflammation or Immune System Disease   Lung Cancer  
/
HY-N16671 Desacetylbufotalin
Desacetylbufotalin (Bufogenin B; Deacetylbufotalin) is a bufadienolide found in Chinese drug "Chan'Su". Desacetylbufotalin shows strong anti-proliferative activity on the of Hela cells (IC50 = 0.01 μM). Desacetylbufotalin can be used for the research of cancer, such as cervical cancer.

Source: 蟾酥

Others  
Cancer  
/
HY-P992200 Anti-CD146 Antibody (AA98)
Anti-CD146 Antibody (AA98) is an antibody targeting CD146 and an angiogenesis inhibitor. Anti-CD146 Antibody (AA98) blocks the dimerization of CD146 as well as its downstream PI3K/AKT, p38 MAPK and NF-κB signaling pathways; it inhibits the expression of MMP9 and ICAM1, epithelial-mesenchymal transition (EMT), and the proliferation, migration and tube formation of endothelial cells. Anti-CD146 Antibody (AA98) enhances radiation-induced cancer cell apoptosis and survival inhibition, reduces tumor microvessel density, and suppresses tumor growth, invasion and vasculogenic mimicry. Anti-CD146 Antibody (AA98) can be used in research related to cervical cancer, liver cancer, malignant phyllodes tumor of the breast, uveal melanoma, leiomyosarcoma, pancreatic cancer, other tumors and angiogenesis.

Species: Human

Transmembrane Glycoprotein   PI3K   Akt   p38 MAPK   NF-κB   MMP   Apoptosis   Caspase   Bcl-2 Family  
Blood or Cardio-cerebrovascular Disease   Liver Cancer   Cervical Cancer   Pancreatic Cancer   Melanoma  
/
HY-182259 Montanastatin
Montanastatin is an antitumor agent that can be isolated from the terrestrial actinomycete Streptomyces anulatus. Montanastatin inhibits the growth of various cancer cells. Montanastatin can be used in research related to lymphocytic leukemia, ovarian cancer, brain cancer, renal cancer, lung cancer, colon cancer and melanoma.
Others  
Lung Cancer   Colorectal Cancer   Leukemia/Lymphoma/Myeloma   Melanoma   Ovarian Cancer   Renal Cancer  
/
HY-133800 Volvaltrate B
Volvaltrate B is an anticancer agent, iridoid, can be obtained from the root of valerian (Valeriana officinalis). Volvaltrate B is effective against ovarian tumors in female mice. Volvaltrate B has the potential to study cancer.
Biochemical Assay Reagents  
Cancer  
/
HY-15947G Ravoxertinib (GMP)
Ravoxertinib GMP is Ravoxertinib (HY-15947) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ravoxertinib (GDC-0994) is an orally active ERK1/2 inhibitor. Ravoxertinib inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma.
ERK   c-Myc   Hexokinase   Lactate Dehydrogenase  
Breast Cancer   Ovarian Cancer   Squamous Cell Carcinoma  
/
HY-Y0317I Sodium sulfate anhydrous, meets analytical specification of Ph. Eur. BP USP
Sodium sulfate anhydrous (Disodium sulfate), meets analytical specification of Ph. Eur. BP USP is an orally active multifunctional ionic salt that serves as a protein precipitant, collagen fibril bundling inducer, and chlorine-free sodium source. Sodium sulfate anhydrous, meets analytical specification of Ph. Eur. BP USP promotes collagen fibril bundling to increase matrix pore size, alters cancer cell morphology and regulates their migration direction via geometric signals, and separates plasma/serum proteins or concentrates proteins at 37°C without causing thermal denaturation. In poultry farming applications, Sodium sulfate anhydrous, meets analytical specification of Ph. Eur. BP USP improves laying performance and eggshell quality, and is safe and effective at an addition level of 0.3-1.5%, while a high concentration of 3.0% causes negative physiological effects. Sodium sulfate anhydrous, meets analytical specification of Ph. Eur. BP USP can be widely applied in scientific research on cervical cancer and related fields.
Biochemical Assay Reagents  
Cervical Cancer  
/
HY-N21630 Phanginin F
Phanginin F is a cassane-type furanoditerpenoid anticancer agent. Phanginin F can be isolated from the seeds of Caesalpinia sappan Linn. Phanginin F exhibits anticancer activity against ovarian cancer, gastric cancer, and non-small cell lung cancer. Phanginin F can be used in research on ovarian cancer, gastric cancer, and non-small cell lung cancer.
Drug Intermediate  
Gastric Cancer   Ovarian Cancer   Non-Small Cell Lung Cancer  
/
HY-D3182 AldRed 588-A
AldeRed 588-A is a fluorescent labeling reagent and a substrate for aldehyde dehydrogenase (ALDH). AldeRed 588-A is metabolized by functionally active ALDH enzymes, thereby specifically labeling viable ALDHbright cell populations with red-shifted fluorescence. AldeRed 588-A supports one-step isolation and sorting of ALDH-expressing cells (including normal stem cells and cancer stem cells), and can be used in combination with green fluorophores for multicolor experimental applications. AldeRed 588-A is widely applicable to research related to various cancers such as bladder cancer, breast cancer, and head and neck cancer.
Fluorescent Dye   Aldehyde Dehydrogenase (ALDH)  
Cancer  
/
HY-P3214 Myosin light chain kinase fragment 11-19 amide
Myosin light chain kinase fragment 11-19 amide (MLCK(11-19) amide) is a substrate-specific peptide inhibitor of MLCK. Myosin light chain kinase fragment 11-19 amide inhibits hypotonicity-induced Ca2+ entry. Myosin light chain kinase fragment 11-19 amide can be used in the research of human cervical cancer.
Others  
Cancer  
/
HY-P11814 cTMTP1
cTMTP1 (Cyclic TMTP1) is the cyclic form of TMTP1 (HY-P11815). TMTP1 is a tumor-targeting peptide that selectively targets highly metastatic tumor cells. The cTMTP1-based [68Ga]Ga-DOTA-cTMTP1 probe is used for visualization of hepatocellular carcinoma. cTMTP1 can form a 68Ga-DOTA radiotracer that accumulates in highly metastatic cervical cancer cells and is used for microPET tumor visualization. cTMTP1 is applicable to research related to hepatocellular carcinoma and cervical cancer.
Radionuclide-Drug Conjugates (RDCs)   Drug Derivative  
Liver Cancer   Cervical Cancer  
/
HY-P11678 HDAC-IN-100
HDAC-IN-100 is a histone deacetylase inhibitor with an IC50 of 0.038 μM against HDAC1, 0.283 μM against HDAC2, and 0.586 μM against HDAC3. HDAC-IN-100 acts as a chemosensitizer and apoptosis inducer, activates caspase 3/7, and reverses Cisplatin (HY-17394) resistance. HDAC-IN-100 exerts antiproliferative effects in ovarian cancer cells and squamous cancer cells. HDAC-IN-100 is applicable for research related to ovarian cancer, squamous cell carcinoma, and Cisplatin (HY-17394)-resistant squamous cell carcinoma.
HDAC   Apoptosis   Caspase  
Ovarian Cancer  
/
HY-N15103 Hydroxymycotrienin B
Hydroxymycotrienin B is an ansamycin group antibiotic (triene-ansamycin) found in culture broths of Bacillus sp. BMJ958-62F4. Hydroxymycotrienin B inhibits HPV-positive cervical cancer cell growth 3~10 times more strongly than HPV-negative cervical cancer cells. Hydroxymycotrienin B can be used for the research of human cervical cancer.

Source: Bacillus sp. BMJ958-62F4

Antibiotic   HPV  
HPV-Positive Cervical Cancer  
/
HY-P990558 BMS-986021
BMS-986021 (BMS-986148 antibody) is a human monoclonal antibody expressed in CHO, targeting Mesothelin. BMS-986021 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.46 kDa. For the isotype control of BMS-986021, refer to Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Others  
Inflammation or Immune System Disease  
/
HY-P992178 ALLO-647
ALLO-647 is a human monoclonal antibody targeting CD52. ALLO-647 transiently and selectively depletes host lymphocytes to promote the proliferation of allogeneic CAR T-cell following infusion. ALLO-647 can be used for the research of B-cell lymphoma and follicular lymphoma.

Species: Human

NF-κB  
Leukemia/Lymphoma/Myeloma  
/
HY-107614G 1-Oleoyl lysophosphatidic acid sodium (GMP)
1-Oleoyl lysophosphatidic acid sodium (GMP) is the GMP-grade form of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). GMP-grade small molecules serve as auxiliary reagents in cell therapy. 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid signaling molecule. 1-Oleoyl lysophosphatidic acid sodium inhibits lysoPLD-catalyzed hydrolysis of lysophosphatidylcholine and FS-3. 1-Oleoyl lysophosphatidic acid sodium activates LPA1 and LPA2, thereby triggering calcium mobilization, NFATc1 translocation, Rho/ROCK activation, Smad2/3 phosphorylation and c-Fos expression. 1-Oleoyl lysophosphatidic acid sodium induces anxiety-like, depression-like and hypoactivity phenotypes, regulates osteoclast cytoskeleton and viability, reduces osteoclast bone resorptive activity, and drives mesenchymal stem cell differentiation into myofibroblast-like cells. 1-Oleoyl lysophosphatidic acid sodium stimulates the secretion of transforming growth factor-β1 and stromal cell-derived factor-1. 1-Oleoyl lysophosphatidic acid sodium is applicable to research related to anxiety, depression and ovarian cancer.
LPL Receptor   ROCK   TGF-beta/Smad   TGF-β Receptor  
Ovarian Cancer   Depression   Anxiety or Fear-Related Disease  
/
HY-P10785 Iturin A-2
Iturin A-2 is a cyclic lipopeptide discovered in B. subtilis and exhibits inhibitory activity against the plant pathogenic fungus P. expansum (MIC = 8 µg/disk). Iturin A-2 is cytotoxic to MCF-7 and BT474 breast cancer cells, as well as HeLa cervical cancer cells, with IC50 values of 66.81, 95.04, and 77.5 µg/mL, respectively. In greenhouse studies, Iturin A-2 at concentrations of 100 and 300 mg/kg Iturin A-2 reduces the lesion area of southern corn leaf blight caused by B. maydis, and in field studies, concentrations of 300 and 500 mg/kg Iturin A-2 reduce the incidence of the disease. Iturin A-2 (12.5 µg/mL) inhibits cell division, but not nuclear division, in isolated fertilized starfish eggs.
Bacterial   Antibiotic  
Infection  
/
HY-P992002 AMT-151 Antibody
AMT-151 Antibody is a monoclonal antibody inhibitor targeting folate receptor α. AMT-151 Antibody can be used to synthesize the antibody-drug conjugate (ADC) AMT-151. AMT-151 Antibody can be used to research related to cancer.

Species: Human

ADC Antibodies  
Cancer  
/
HY-13673S1 Goserelin-d7
Goserelin-d7 (ICI 118630-d7) is deuterium labeled Goserelin. Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer.
Isotope-Labeled Compounds   Apoptosis   GnRH Receptor  
Cancer   Metabolic or Endocrine Disease  
/
HY-P11815 TMTP1
TMTP1 is a five-amino acid (NVVRQ) tumor-homing peptide. TMTP1 slows the growth of tumor cells. TMTP1 serves as a diagnostic marker for hematological malignancies and acts as an anticancer drug carrier to enhance the cellular uptake rate of nanocarriers in tumor tissues. TMTP1 is applicable to research related to hematological malignancies, lymphoma, chronic myeloid leukemia, cervical cancer, and ovarian cancer.
Others  
Cervical Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer  
/
HY-N3446 IVHD-valtrate
IVHD-valtrate, an active Valeriana jatamansi derivative, is against human ovarian cancer cells in vitro and in vivo. IVHD-valtrate induces cancer cells apoptosis and arrests the ovarian cancer cells in the G2/M phase. IVHD-valtrate has the potential to be a novel chemotherapeutic agent for the human ovarian cancer research.
Apoptosis  
/
HY-P0121A ReACp53 scrambled peptide
ReACp53 scrambled peptide is a negative control for ReACp53 (HY-P0121). ReACp53 scrambled peptide can be used in the study of ovarian cancer.
MDM-2/p53  
Cancer  
/
HY-P11036 p53-hDM2 cyclic peptide inhibitor 16e
p53-hDM2 cyclic peptide inhibitor 16e is a p53-hDM2 cell-permeable peptide inhibitor with an IC50 of 9.24 nM for hDM2. p53-hDM2 cyclic peptide inhibitor 16e can be used for cancers like breast, colorectal and cervical cancers research.
MDM-2/p53  
Cancer  
/
HY-13632S Exemestane-d2
Exemestane-d2 is the deuterium labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research.
Isotope-Labeled Compounds   Cytochrome P450  
Metabolic or Endocrine Disease  
/
HY-P992291 Anti-PL2L60 Antibody (KAO3)
Anti-PL2L60 Antibody (KAO3) is a PL2L60-targeting antibody. Anti-PL2L60 Antibody (KAO3) binds to PL2L60 expressed on tumor cell surfaces, blocking its tumor-promoting functions. Anti-PL2L60 Antibody (KAO3) arrests tumor cell cycle and induces cancer cell apoptosis. Anti-PL2L60 Antibody (KAO3) activates complement to mediate tumor cell lysis. Anti-PL2L60 Antibody (KAO3) can be used for the research of lymphoma, breast cancer, lung cancer, cervical cancer, colon cancer, and melanoma[1].

Species: Human

Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Cervical Cancer   Leukemia/Lymphoma/Myeloma   Melanoma  
/
HY-P12121 HB43
HB43 is a synthetic amphipathic cationic α-helical peptide, as well as an antibacterial/anticancer peptide. HB43 reduces the number of Methicillin (HY-121544)-resistant Staphylococcus aureus in biofilms in a dose-dependent manner. When loaded into chitosan nanoparticles, it achieves sustained release, and this effect is particularly pronounced under acidic conditions.
Bacterial  
Cancer   Bacterial Infection  
/
HY-D3186 HMRef-βGal
HMRef-βGal is a fluorescent probe and a substrate responsive to β-galactosidase (β-galactosidase) (Ex/Em=498 nm/505-600 nm). After being cleaved by β-galactosidase, HMRef-βGal triggers significant fluorescence enhancement via intramolecular spirocyclic function regulation. HMRef-βGal generates bright fluorescence in cancer cells with elevated β-galactosidase activity, enabling visualization of tiny peritoneal metastases in mouse models. HMRef-βGal exhibits low in vitro cytotoxicity and low acute in vivo toxicity in mice. HMRef-βGal can be used for preclinical fluorescence-guided diagnosis and cytoreductive surgery of peritoneal metastases, including compatibility with real-time naked-eye detection and endoscopic imaging, as well as for studies related to peritoneal metastases of ovarian cancer.
Fluorescent Dye   Glycosidase  
Ovarian Cancer  
/
HY-B0021S1 Doxifluridine-d3
Doxifluridine-d3 is deuterated labeled Doxifluridine (HY-B0021). Doxifluridine has anticancer activity. Doxifluidine is a 5-FU prodrug. Doxifluridine is a thymidine synthase inhibitor. Doxifluridine can enhance tumor inhibition by synergizing with a variety of drugs.
Thymidylate Synthase   Isotope-Labeled Compounds  
/
HY-P992270 Anti-MUC16 Antibody (MMUC3333A)

Species: Human

/
HY-187304S [U-15N]-AFP
[U-15N]-AFP is the 15N-labeled AFP. Abnormally elevated levels of alpha-fetoprotein (AFP) serve as a key indicator for the diagnosis and monitoring of primary liver cancer and tumors such as testicular and ovarian cancers. This isotope can be used in NMR studies to investigate disease mechanisms and in mass spectrometry analysis.
Isotope-Labeled Compounds  
Ovarian Cancer  
/
HY-171269 Anetumab-MMAE
Anetumab-MMAE is an antibody-drug conjugate (ADC) (Anetumab antibody (HY-P99352), Linker: VC linker, Payload: MMAE (HY-15162)). Anetumab is an anti-mesothelin (MSLN) antibody.
Mesothelin   Antibody-Drug Conjugates (ADCs)  
Cancer  
/
HY-D1877 ZY-1
ZY-1 is a control molecule of ZY-2 (HY-D1876, a PKM2 fluorescent probe). ZY-1 shows a low fluorescence emission in HeLa, a cervical cancer cell abundant in PKM2 expression.
Pyruvate Kinase  
/
HY-D3165 DCM-gal-CF
DCM-gal-CF is a fluorescent probe containing a DCM fluorophore scaffold and a D-galactose recognition moiety. DCM-gal-CF itself shows weak fluorescence, and its fluorescence is enhanced after cleavage by β-galactosidase. DCM-gal-CF can be used to detect β-galactosidase activity.
Fluorescent Dye  
Cancer  
/
HY-P990466 Anti-Mesothelin Antibody
Anti-Mesothelin Antibody is a humanized antibody expressed in CHO that targets Mesothelin. The Anti-Mesothelin Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-Mesothelin Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Mesothelin  
Inflammation or Immune System Disease  
/
HY-P11129 MAGE-A4 (286-294)
MAGE-A4 (286-294) is a polypeptide derived from the 286th to 294th amino acids of the MAGE-A4 protein. MAGE-A4 (286-294) binds HLA-­A*02 with an affinity of 560.08 nM and an IC50 of 8.52 nM. MAGE-A4 (286-294) can be detected in various types of cancers (such as esophageal cancer, lung squamous cell carcinoma, bladder cancer). MAGE-A4 (286-294) can be used to produce CAR-T cells and to develop CAR-T cell therapy.
Others  
Cancer  
/
HY-W1123936C DBCO-PEG2000-FA
DBCO-PEG2000-FA (DBCO-PEG2000-Folate) is a multifunctional bioconjugation reagent, which is a copolymer of DBCO and Folic acid (FA) (HY-16637) and can target folate receptors (FR). Folate receptors are highly overexpressed on the surface of many cancer cells (such as lung cancer, nasopharyngeal cancer, ovarian cancer, etc.), but exhibit extremely low expression levels in normal tissues. DBCO-PEG-FA can be used for click chemistry conjugation via its DBCO terminal, and thus applies to various bioconjugation and drug delivery applications.
Folate Receptor (FR)  
/
HY-N19113 Emindole SB
Emindole SB is an anticancer agent. Emindole SB can be isolated from Penicillium species. Emindole SB exerts anticancer effects against ovarian cancer, breast cancer and lymphoma. Emindole SB shows no toxicity to Caenorhabditis elegans. Emindole SB can be used in studies related to ovarian cancer, lymphoma and breast cancer.

Source: Aspergillus oryzae

Endogenous Metabolite  
Breast Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Fungal Infection   Parasitic Infection  
/
HY-P992441 PHST001
PHST001 is a humanized anti-CD24 antibody. PHST001 binds cell-surface CD24, blocks CD24-Siglec10 interaction, and engages Fc receptors to promote macrophage-mediated tumor cell phagocytosis. PHST001 inhibits growth of breast cancer and ovarian cancer, and reduces metastatic lesions in mouse xenograft models. PHST001 can be used for the research of triple negative breast cancer, HER2+ breast cancer, metastatic tumors, and ovarian cancer.

Species: Human

Transmembrane Glycoprotein  
Ovarian Cancer   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer  
/
HY-P992004 KHK2805
KHK2805 (RA15-7) is a humanized antibody against folate receptor α (FOLR1), with a Kd of 0.647 nM for human FOLR1. KHK2805 binds to a unique epitope of FOLR1 and mediates antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity against FOLR1-expressing cells. KHK2805 exhibits cytotoxicity against both ovarian cancer cells and Platinum (HY-W096169D)-resistant ovarian cancer cells. KHK2805 can be used for the research of tumors such as ovarian cancer.

Species: Human

Folate Receptor (FR)  
Cancer  
/
HY-118834 Teleocidin A1
Teleocidin A1 (Lyngbyatoxin A) is a PKC activator with a Ki value of 0.11 nM for binding to the PKCδ-C1B peptide. Teleocidin A1 exhibits anticancer activity against cervical cancer and leukemia. Teleocidin A1 can induce seaweed dermatitis, food poisoning and local skin toxicity. Teleocidin A1 can be used in studies related to cervical cancer, seaweed dermatitis and food poisoning.

Source: Streptomyces

PKC  
Inflammation or Immune System Disease   Cervical Cancer   Leukemia/Lymphoma/Myeloma  
/
HY-N21721 Cordylane C
Cordylane C is a Cassane-type diterpenoid compound. Cordylane C is isolated from Cordyla madagascariensis ssp. madagascariensis. Cordylane C shows no significant anticancer activity against ovarian cancer. Cordylane C is used in the research of ovarian cancer.
Others  
Ovarian Cancer  
/
HY-160065F FAM-sgc8c aptamer sodium
FAM-sgc8c aptamer sodium is a 5-FAM labeled sgc8c aptamer sodium (HY-160065). sgc8c aptamer sodium is an aptamer that specifically targets the human protein tyrosine kinase PTK-7, which is mainly expressed on cervical cancer HeLa cells. Binding of FAM-sgc8c aptamer sodium to PTK-7 induces the assembly of nanotags on the cell surface, resulting in strong fluorescence and SERS signals.
Others  
Cancer  
/
HY-P991417 LYN00101
LYN00101 is a human monoclonal antibody (mAb) targeting VEGFA. LYN00101 can be used in Cervical cancer, Colorectal cancer, Gastric cancer and Ovarian cancer research.

Species: Human

VEGFR  
Cancer  
/
HY-N16523 Ferruginoside C
Ferruginoside C is a phenylethanoid. Ferruginoside C can be isolated from V. leiocarpum. Ferruginoside C shows potent alpha-glucosidase inhibitory activity with an IC50 of 19.93 μM. Ferruginoside C shows antioxidant activities. Ferruginoside C can be used in the research of cervical cancer, ovarian cancer, and colon cancer.
Glycosidase  
Colorectal Cancer   Cervical Cancer   Ovarian Cancer  
/
HY-N11010 Eclalbasaponin IV
Eclalbasaponin IV is a triterpenoid that can be isolate from the aerial parts of Eclipta prostrata. Eclalbasaponin IV shows antitumor activity in human ovarian cancer cells.
Others  
/
HY-W1123936E DBCO-PEG5000-FA
DBCO-PEG5000-FA (DBCO-PEG5000-Folate) is a multifunctional bioconjugation reagent, which is a copolymer of DBCO and Folic acid (FA) (HY-16637) and can target folate receptors (FR). Folate receptors are highly overexpressed on the surface of many cancer cells (such as lung cancer, nasopharyngeal cancer, ovarian cancer, etc.), but exhibit extremely low expression levels in normal tissues. DBCO-PEG-FA can be used for click chemistry conjugation via its DBCO terminal, and thus applies to various bioconjugation and drug delivery applications.
Folate Receptor (FR)  
/
HY-P11854 SWQIGGN
SWQIGGN is an oligopeptide targeting ovarian cancer cells. SWQIGGN inhibits the viability, proliferation, migration, invasion and cell adhesion of ovarian cancer cells and promotes apoptosis. SWQIGGN reduces ascites volume and tumor nodule formation in mouse models. SWQIGGN can be used in studies related to ovarian cancer.
Apoptosis  
Ovarian Cancer  
/
HY-N3855 Erythrabyssin II
Erythrabyssin II (EL-19) is a potent late-stage autophagy inhibitor that blocks the fusion of autophagosome and lysosome. Erythrabyssin II leads to the accumulation of autophagic substrates and does not impair lysosomal pH or lysosomal enzyme activity. Erythrabyssin II suppresses ovarian cancer organoid activity and induces apoptosis. Erythrabyssin II can be used for the study of ovarian cancer.
Autophagy   Apoptosis  
/
HY-13673S Goserelin-d10
Goserelin-d10 (ICI 118630-d10) is deuterium labeled Goserelin. Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer.
Isotope-Labeled Compounds  
Cancer   Metabolic or Endocrine Disease  
/
HY-P991315 Anti-MSLN/Mesothelin (h7D9.v3)
Anti-MSLN/Mesothelin (h7D9.v3) is a human monoclonal antibody (mAb) targeting MSLN. Anti-MSLN/Mesothelin (h7D9.v3) can be used in ovarian cancer, mesothelioma, and pancreatic cancer research.

Species: Human

Cancer  
/
HY-P991839 Anti-CD19 Antibody (FMC63)
Anti-CD19 Antibody (FMC63) is an antibody that binds to CD19, with a human Kd value ranging from 0.42 nM to 149 nM. Anti-CD19 Antibody (FMC63) mediates tumor cell killing, cytokine secretion, stable CAR expression, T cell activation and memory differentiation. Anti-CD19 Antibody (FMC63) fails to eliminate lymphoma cells carrying CD19 point mutations or co-expressing FMC63-CAR19, induces higher levels of activation-induced cell death, and reduces cell persistence. Anti-CD19 Antibody (FMC63) can be used in research related to B-cell non-Hodgkin's lymphoma, B-cell acute lymphoblastic leukemia, relapsed or refractory diffuse large B-cell lymphoma, etc.

Species: Human

CD19  
Acute Lymphoblastic Leukemia   Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma  
/
HY-P990830 Anti-MUC16 Antibody (VK8)
Anti-MUC16 Antibody (VK8) is a kind of mouse IgG1 κ chimeric antibody inhibitor, targeting to human MUC16. Anti-MUC16 Antibody (VK8) reacts with human MUC16 also known as carbohydrate antigen 125 (CA125). Anti-MUC16 Antibody (VK8) Anti-MUC16 Antibody (VK8) can be used for detection of tumor marker, such as ovarian cancer.

Species: Human

Mucin  
Cancer  
/
HY-13632S2 Exemestane-d3
Exemestane-d3 is the deuterium labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research.
Isotope-Labeled Compounds   Cytochrome P450  
Metabolic or Endocrine Disease  
/
HY-N2072R Crocetin (Standard)
Crocetin (Standard) (TransCrocetin (Standard) ) is an aglycone of crocin. Crocetin (Standard) is orally active and brain-penetrant. Crocetin (Standard) shows strong NMDA receptor affinity and channel opening activity. Crocetin (Standard) can downregulate the proinflammatory cytokines and COX-2 exoression. Crocetin (Standard) can inhibit apoptosis and activation of MAPK. Crocetin (Standard) can delay delays brain and body aging. Crocetin (Standard) can be used for the researches of cancer, neurological disease and inflammation, such as cervical cancer and ischemia.
iGluR   Reference Standards   Apoptosis   COX   p38 MAPK  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-105791S Sulazepam-d5
Sulazepam-d5 is a deuterium labeled Sulazepam (HY-105791). Sulazepam is a selective ovarian cancer G protein-coupled receptor (OGR1) agonist.
Isotope-Labeled Compounds   GPR68  
Neurological, Eye or Ear Disease  
/
HY-P99109 Zimberelimab
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma.

Species: Human

PD-1/PD-L1  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
/
HY-W1123936B DBCO-PEG1000-FA
DBCO-PEG1000-FA (DBCO-PEG1000-Folate) is a multifunctional bioconjugation reagent, which is a copolymer of DBCO and Folic acid (FA) (HY-16637) and can target folate receptors (FR). Folate receptors are highly overexpressed on the surface of many cancer cells (such as lung cancer, nasopharyngeal cancer, ovarian cancer, etc.), but exhibit extremely low expression levels in normal tissues. DBCO-PEG-FA can be used for click chemistry conjugation via its DBCO terminal, and thus applies to various bioconjugation and drug delivery applications.
Folate Receptor (FR)  
Cancer  
/
HY-W248590 IR-775 chloride
IR-775 chloride is a cyanine dye with near-infrared absorption (Ex/Em = 775/795 nm). IR-775 chloride acts as a photosensitizer or photothermal agent, and induces apoptosis via generating ROS or exerting photothermal effects upon irradiation; its combination with 2-methoxyestradiol (HY-12033) inhibits SOD2 to enhance photodynamic therapy (PDT) efficacy, and its liposomal encapsulation enables phytotherapy-photothermal therapy (PTT) synergy. IR-775 chloride is applicable for investigating PDT/PTT and near-infrared fluorescence imaging in ovarian cancer and breast cancer.
Fluorescent Dye   Photosensitizer   Apoptosis   Reactive Oxygen Species (ROS)   SOD  
Breast Cancer   Ovarian Cancer  
/
HY-P992121 Nilvanstomig
Nilvanstomig (ZG005) is an antibody targeting PD-1 and TIGIT. Nilvanstomig blocks the PD-1/TIGIT pathway, thereby promoting the synergistic activation of T cells and enhancing the anti-tumor activity of NK cells. Nilvanstomig is applicable to relevant research on advanced cervical cancer.

Species: Human

PD-1/PD-L1   Transmembrane Glycoprotein  
Cervical Cancer  
/
HY-P991689 Girancitug
Girancitug is a humanized IgG1κ monoclonal antibody inhibitor targeting VEGFR2/KDR/CD309. Girancitug effectively inhibits angiogenesis. Girancitug can be used for anti-angiogenic therapy in cancers like colorectal and ovarian cancer research.

Species: Human

VEGFR  
Cancer  
/
HY-W014989 Thioglucose
Thioglucose is a thiosugar with antioxidant properties. Thioglucose acts as an H2S/polysulfide donor to elevate intracellular sulfane sulfur levels and promote hydropersulfide formation. Thioglucose reduces the endocytosis of gold nanoparticles by phagocytes, enhances cytotoxicity and improves biocompatibility by increasing their adsorption on the surface of cancer cells. Thioglucose can be engineered into a stimulus-responsive prodrug or functional reagent for the development of targeted nanocarriers, and is used in studies related to human breast adenocarcinoma and cervical cancer.
Biochemical Assay Reagents  
Breast Cancer   Cervical Cancer  
/
HY-13673S2 Goserelin-d7 TFA
Goserelin-d7 (TFA) is deuterium labeled Goserelin. Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer.
Isotope-Labeled Compounds   GnRH Receptor   Apoptosis  
Cancer   Metabolic or Endocrine Disease  
/
HY-121794 Avarol
Avarol is a sesquiterpene hydroquinone that can be isolated from Dysidea avara sponge. Avarol has the potential for the research of ehrlich carcinoma (EC) and cervical cancer (CC-5).

Source: Dysidea avara

Apoptosis   NF-κB  
Cancer  
/
HY-B0464S Hydralazine-d4 hydrochloride
Hydralazine-d4 hydrochloride is the deuterium labeled Hydralazine hydrochloride. Hydralazine hydrochloride is an orally active, blood-brain barrier-permeable DNA methyltransferase inhibitor with vasodilatory, arterial smooth muscle relaxant and hypotensive activities. Hydralazine hydrochloride reactivates silenced tumor suppressor genes via mediating DNA demethylation, while exerting neuroprotective and anti-inflammatory properties. Hydralazine hydrochloride inhibits NOS-2 (iNOS) and COX-2, and reduces the production of NO and PGEE2; meanwhile, Hydralazine hydrochloride scavenges reactive oxygen species and inhibits macrophage activation. Hydralazine hydrochloride alleviates motor dysfunction, neuropathic inflammatory pain, and formalin-induced somatic and emotional pain responses. In addition, Hydralazine hydrochloride directly induces DNA strand breaks and sister chromatid exchange, exhibiting certain mutagenic characteristics. Hydralazine hydrochloride has been widely used in studies on hypertension, various cancers (such as cervical cancer, leukemia), spinal cord injury and the mechanisms of inflammatory pain.
Isotope-Labeled Compounds   PGE synthase   NO Synthase   Reactive Oxygen Species (ROS)   DNA Methyltransferase   COX  
Blood or Cardio-cerebrovascular Disease  
/
HY-P991088 HPN536
HPN536 is a trispecific, T-cell-activating protein-based construct, which binds to mesothelin-expressing tumor cells, CD3ε on T cells, and to serum albumin. HPN536 specifically redirects T cells for potent redirected lysis of mesothelin-expressing cancer cells with concomitant T-cell activation.

Species: Human

CD3  
Cancer  
/
HY-W106860 9H-Carbazole-3-carbaldehyde
9H-Carbazole-3-carbaldehyde (3-Formylcarbazole) is a carbazole compound and an anticancer agent. 9H-Carbazole-3-carbaldehyde is present in the stems of Clausena lansium (Lour.) Skeels. 9H-Carbazole-3-carbaldehyde can be used in the research of cervical cancer, leukemia, non-small cell lung cancer and liver cancer.
Drug Intermediate  
Liver Cancer   Cervical Cancer   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer  
/
HY-P992133 Sutantatug
Sutantatug (SYS6002 Antibody) is a monoclonal antibody targeting Nectin-4, and serves as the antibody moiety of the ADC CRB-701. Sutantatug is applicable to the research of Nectin-4-positive solid tumors, urothelial carcinoma and cervical cancer. The corresponding isotype control for Sutantatug is Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

ADC Antibodies   Nectin-4  
Cervical Cancer   Urothelial Cancer  
/
HY-B0464S1 Hydralazine-d5 hydrochloride
Hydralazine-d5 (hydrochloride) is deuterium-labeled Hydralazine (hydrochloride) (HY-B0464). Hydralazine hydrochloride is an orally active, blood-brain barrier-permeable DNA methyltransferase inhibitor with vasodilatory, arterial smooth muscle relaxant and hypotensive activities. Hydralazine hydrochloride reactivates silenced tumor suppressor genes via mediating DNA demethylation, while exerting neuroprotective and anti-inflammatory properties. Hydralazine hydrochloride inhibits NOS-2 (iNOS) and COX-2, and reduces the production of NO and PGEE2; meanwhile, Hydralazine hydrochloride scavenges reactive oxygen species and inhibits macrophage activation. Hydralazine hydrochloride alleviates motor dysfunction, neuropathic inflammatory pain, and formalin-induced somatic and emotional pain responses. In addition, Hydralazine hydrochloride directly induces DNA strand breaks and sister chromatid exchange, exhibiting certain mutagenic characteristics. Hydralazine hydrochloride has been widely used in studies on hypertension, various cancers (such as cervical cancer, leukemia), spinal cord injury and the mechanisms of inflammatory pain.
Isotope-Labeled Compounds   PGE synthase   NO Synthase   Reactive Oxygen Species (ROS)   DNA Methyltransferase   COX  
Cancer  
/
HY-P0121B ReACp53 scrambled peptide TFA
ReACp53 scrambled peptide TFA is a negative control for ReACp53 (HY-P0121). ReACp53 scrambled peptide can be used in the study of ovarian cancer.
MDM-2/p53  
Cancer  
/
HY-P990870 Anti-CD19 Antibody (4G7)
Anti-CD19 Antibody (4G7) is an anti-human CD19 IgG1 monoclonal antibody. Anti-CD19 Antibody (4G7) reduces the killing effect of CAR T cells on Raji cells. Anti-CD19 Antibody (4G7) can be used for research on immunology. Anti-CD19 Antibody (4G7) is often used in flow cytometry. The recommend isotype control of Anti-CD19 Antibody (4G7): Mouse IgG1 kappa, Isotype Control (HY-P99977).

Species: Mouse

CD19   IFNAR   Interleukin Related  
Inflammation or Immune System Disease  
/
HY-17386S1 Rosiglitazone-d4
Rosiglitazone-d4 is deuterated labeled Rosiglitazone (HY-17386). Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC50: 60 nM, Kd: 40 nM). Rosiglitazone is an TRPC5 activator (EC50: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer.
TRP Channel   Ferroptosis   PPAR   Autophagy   Apoptosis   Isotope-Labeled Compounds  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-W001603 Ethyl diethoxyacetate
Ethyl diethoxyacetate is a reagent used in organic synthesis. Ethyl diethoxyacetate has moderate antiproliferative effects on cervical cancer and liver cancer.
Biochemical Assay Reagents  
Cancer  
/
HY-P99825 Relfovetmab
Relfovetmab is a monoclonal antibody and also serves as a single-chain variable fragment component for engineering chimeric antigen receptors (CAR) in modified CAR-T cells. Relfovetmab can be used in studies of cancer and immune disorders.

Species: Feline

Others  
Cancer   Inflammation or Immune System Disease  
/
HY-W011654 4-Aminophenyl-β-D-galactopyranoside, 98%
4-Aminophenyl-β-D-galactopyranoside, 98% is a highly efficient substrate for β-galactosidase. It is specifically hydrolyzed by this enzyme to release galactose and electroactive p-aminophenol. 4-Aminophenyl-β-D-galactopyranoside, 98% is widely used in colorimetric and electrochemical assays for detecting β-galactosidase activity and determining enzyme kinetics, such as in biosensing fields including cellular senescence, pathogen and contaminant detection. In addition, since β-galactosidase is often overexpressed in primary ovarian cancer, 4-Aminophenyl-β-D-galactopyranoside, 98% can also be applied to related research on primary ovarian cancer.
Glycosidase  
Ovarian Cancer   Cellular Senescence  
/
HY-W115609 N-Phenylbenzamide
N-Phenylbenzamide (N-Benzoylaniline) is a compound skeleton. N-Phenylbenzamide can be used for the researches of cancer and infection, such as enterovirus and cervical cancer.
Enterovirus   Biochemical Assay Reagents  
Infection  
/
HY-148979 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphorylethanolamine
1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphorylethanolamine (SAPE) is a fluorescent reporter that specifically binds biotin. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphorylethanolamine produces a detectable fluorescent signal to quantify target factors. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphorylethanolamine can be used for the research of primary liver cancer, cervical cancer.
Fluorescent Dye  
Liver Cancer   Cervical Cancer  
/
HY-P990929 Misitatug
HY-P990929 is an MSLN-targeting IgG1κ type chimeric antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Mesothelin  
Inflammation or Immune System Disease  
/
HY-P99594 Socazolimab
Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma.

Species: Human

PD-1/PD-L1  
Cancer  
/
HY-168973 Fexlamose
Fexlamose (AER-01) is a thiol-modified carbohydrate agent with mucolytic property. Fexlamose cleaves disulfides to cause mucolysis. Fexlamose can be used for researchs of chronic obstructive pulmonary disease (COPD) and muco-obstructive lung diseases (MOLD).
Mucin  
Inflammation or Immune System Disease  
/
HY-P2508 MUC1, mucin core
MUC1, mucin core is the region of the MUC1 mucin core. MUC1 is a type I transmembrane glycoprotein, and is overexpressed and aberrantly glycosylated in carcinoma cells. MUC1, mucin core protein binds to domain 1 of ICAM-1.
Mucin  
/
HY-P990833 Anti-Mesothelin Antibody (YP218)
Anti-Mesothelin Antibody (YP218) is a rabbit-derived antibody, targeting to human Mesothelin. Anti-Mesothelin Antibody (YP218) reacts with a epitope in the C-terminal end close to the tumor cell surface of human mesothelin (MSLN). Anti-Mesothelin Antibody (YP218) can be used for the research of cancer, such as A431/H9 tumor.

Species: Human

Mesothelin  
Cancer  
/
HY-114491 Rineterkib
Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF.
ERK   Raf  
/
HY-P11303 PADRE peptide
PADRE peptide is a pan-HLA-DR binding epitope and immunostimulant. PADRE peptide binds to the peptide-binding groove of MHC class II molecules for presentation to CD4+ T cells, thereby effectively stimulating specific immune responses. PADRE peptide not only enhances anti-tumor immune responses, inhibits tumor growth and prolongs survival; it also significantly increases the frequency of E7-specific CD8+ T cells and improves therapeutic efficacy against TC-1 tumors when used in combination with E7 peptide-based vaccines and poly (I:C). The intensity of the immune response induced by PADRE peptide is lower than that of the Ii-PADRE DNA vaccine, and it fails to enhance the immune effect of CRT-E7 DNA. PADRE peptide is widely applicable to research on related tumors such as melanoma, glioblastoma and cervical cancer.
CD74   MHC  
Cervical Cancer   Glioblastoma  
/
HY-P99591 Sontuzumab
Sontuzumab (AS1402) is a humanizedised IgG1κ MUC1 specific monoclonal antibody. Sontuzumab binds the extracellular MUC1 peptide sequence PDTR with a Kd of ~1 nM. Sontuzumab can be used for the research of breast cancer.

Species: Human

Mucin  
Breast Cancer  
/
HY-120967 (2S)-OMPT triethylamine, in ethanol:chloroform (1:1), 98%
(2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98%, Lysophosphatidic acid analogue, is a LPA3 G-protein-coupled receptor agonist. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% selectively activates LPA3 G-protein-coupled receptor to trigger downstream cellular signaling events. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% induces calcium, IL-6 release in cancer cells and activates MAPK and Akt signaling pathways. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% can be used for the research of ovarian cancer.
p38 MAPK   Akt   Interleukin Related  
Cancer  
/
HY-P991143 Ixotatug
Ixotatug (TORL-1-23 Antibody) is a monoclonal antibody targeting claudin-6 (CLDN6) that serves as the antibody component of the ADC drug Ixotatug vedotin (TORL-1-23). Ixotatug is applicable to research related to various cancers including ovarian cancer.

Species: Human

Claudin   ADC Antibodies  
Cancer  
/
HY-141606 Anetumab ravtansine
Anetumab ravtansine (BAY 94-9343) is a selective and highly potent antibody-drug conjugate (ADC) to target maytansinoid tubulin. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models.
Microtubule/Tubulin   Antibody-Drug Conjugates (ADCs)  
/
HY-P990690 Volrustomig
Volrustomig (MEDI-5752) is a human IgG1 κ monoclonal antibody targeting CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1 internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1+ T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1+ B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer.

Species: Human

PD-1/PD-L1   CTLA-4  
Gastric Cancer   Liver Cancer   Cervical Cancer   Non-Small Cell Lung Cancer  
/
HY-W020952 Palladium(Ⅱ) acetylacetonate
Palladium(II) acetylacetonate is a metal-organic complex. Palladium(II) acetylacetonate upregulates the expression of GRP78, ATF-4, XBP-1, CHOP, and phosphorylated c-Jun. Palladium(II) acetylacetonate induces Apoptosis. Palladium(II) acetylacetonate has anticancer effects against non-small cell lung cancer, gastric cancer, leukemia, and cervical cancer.
Biochemical Assay Reagents   HSP   Eukaryotic Initiation Factor (eIF)   IRE1   JNK   Apoptosis  
Cancer  
/
HY-W020958 Ru(acac)3
Ru (acac) 3 (Tris (acetylacetonato) ruthenium (III)) is a caspase-3 activator and Apoptosis inducer. Ru (acac) 3 exerts growth inhibitory effects on various cell lines in vitro by inhibiting DNA/RNA synthesis and inducing mild reversible S-phase cell cycle arrest. Ru (acac) 3 is commonly used in research related to ovarian cancer, osteosarcoma, cervical cancer, melanoma, and other fields.
Caspase   Apoptosis  
Cervical Cancer   Ovarian Cancer  
/
HY-P1907 Human Papillomavirus (HPV) E7 protein (49-57)
Human Papillomavirus (HPV) E7 protein (49-57) is a cytotoxic T lymphocyte (CTL) epitope peptide derived from HPV16 E7 protein (sequence: RAHYNIVTF). Human Papillomavirus (HPV) E7 protein (49-57) induces E749-57-specific CTL responses. Human Papillomavirus (HPV) E7 protein (49-57) can be used for the research of cervical cancer.
HPV  
Cervical Cancer  
/
HY-P99262 Imalumab
Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer.

Species: Human

Macrophage migration inhibitory factor (MIF)  
Ovarian Cancer  
/
HY-P99237 Sofituzumab
Sofituzumab (MMUC 1206A) is an anti-MUC16 antibody with a Kd of 0.3-0.9 nM. Sofituzumab can bind multiple adjacent antibody molecules to the repeat sequences of the same MUC16 molecule. Sofituzumab exhibits no anti-tumor activity in the HPAC pancreatic adenocarcinoma xenograft model.

Species: Human

Mucin  
Pancreatic Cancer  
/
HY-B0264 Guaifenesin
Guaifenesin (Guaiacol glyceryl ether), a constituent of guaiac resin from the wood of Guajacum officinale Linné, is an expectorant. Guaifenesin can alleviate cough discomfortby increasing sputum volume and decreasing its viscosity, thereby promoting effective cough.
Mucin  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Viral Infection  
/
HY-177442 DS-3939a
DS-3939a (DS-3939) is an anti-TA-MUC1 (tumor-associated mucin-1) antibody-drug conjugate (ADC). DS-3939a consists of a humanized anti-TA-MUC1 IgG1 monoclonal antibody Gatipotuzumab ( HY-P99634), a stable and cleavable tetrapeptide-based linker (Gly-Gly-Phe-Gly), and a DNA topoisomerase I inhibitor payload (DXd) (HY-13631D), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). DS-3939a inhibits the growth of TA-MUC1-positive cancer cells (CFPAC-1, NCI-H2110) by inducing DNA damage and apoptosis. DS-3939a exhibits significant antitumor activity in a variety of TA-MUC1-expressing advanced solid tumors. DS-3939a can be used for the study of TA-MUC1-expressing advanced cancers.
Antibody-Drug Conjugates (ADCs)   Mucin   Topoisomerase   Apoptosis  
/
HY-P99352 Anetumab
Anetumab (Anti-MSLN Antibody) is a fully humanized anti mesothelin (MSLN) IgG1 antibody. Anetumab (Anti-MSLN Antibody) can be used to synthesize the ADC molecule Anetumab ravtansine (HY-141606). Anetumab (Anti-MSLN Antibody) can be used for the research of cancer.

Species: Human

Mesothelin   ADC Antibodies  
Cancer  
/
HY-P99828 Cofetuzumab
Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. The expression system of Cofetuzumab is typically CHO (Chinese hamster ovary) cells. Cofetuzumab downregulates PTK7 expression, modulates its downstream signaling pathways, and inhibits tumor sphere formation of ovarian cancer cells. Cofetuzumab can be used to synthesize the ADC molecule Cofetuzumab pelidotin (HY-P99829). Cofetuzumab is applicable to the research of tumors such as ovarian cancer.

Species: Human

ADC Antibodies   RET   PERK   ROR  
Ovarian Cancer  
/
HY-P99539 Ubamatamab
Ubamatamab (REGN4018) is a humanized bispecific antibody targeted against Mucin 16 (MUC16) and CD3. Ubamatamab demonstrates potent antitumor activity.

Species: Human

CD3  
Cancer  
/
HY-P991097 Pumitamig
Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.

Species: Human

VEGFR   PD-1/PD-L1  
Ovarian Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
/
HY-P70856 Mesothelin Protein, Mouse (HEK293, His)
Mesothelin Protein, in its membrane-anchored forms, is implicated in cellular adhesion, suggesting a potential role in mediating cell interactions. Additionally, Megakaryocyte-potentiating factor (MPF) enhances megakaryocyte colony formation, indicating its involvement in the development of these specialized blood cell colonies. Mesothelin Protein, Mouse (HEK293, His) is the recombinant mouse-derived Mesothelin protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Mouse; Source: HEK293

Receptor Proteins Cell Adhesion Molecules (CAMs)

/
HY-P700961 CA125 Protein, Human (685a.a, HEK293, His)
The CA125 protein acts by binding to MSLN and plays a crucial role in forming a protective and lubricating barrier on mucosal surfaces. This interaction promotes heterotypic cell adhesion and is suggested to play an important role in peritoneal metastasis of ovarian cancer. CA125 Protein, Human (685a.a, HEK293, His) is the recombinant human-derived CA125 protein, expressed by HEK293 , with C-His labeled tag.

Species: Human; Source: HEK293

CAR-T Related Proteins CA-125

/
HY-P78369 FITC-Labeled Mesothelin Protein, Human (HEK293, Fc)
Mesothelin Protein, especially in its membrane-anchored forms, potentially mediates cellular adhesion, implicating its role in cell interactions. Furthermore, the associated Megakaryocyte-potentiating factor (MPF) actively enhances in vitro megakaryocyte colony formation, indicating its participation in fostering specialized blood cell colonies' development. FITC-Labeled Mesothelin Protein, Human (HEK293, Fc) is the recombinant human-derived FITC-Labeled Mesothelin protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Human; Source: HEK293

Receptor Proteins Fluorescent-labeled Recombinant Proteins Cell Adhesion Molecules (CAMs)

/
HY-P703091 BRCA1 Protein, Human
BRCA1 Protein, Human is the recombinant human-derived BRCA1, expressed by E. coli, with tag free labeled tag.

Species: Human; Source: E. coli

Enzymes & Regulators Transferases (EC 2)

/
HY-P700960 CA125 Protein, Human (Biotinylated, 685a.a, HEK293, His-Avi)
The CA125 protein acts by binding to MSLN and plays a crucial role in forming a protective and lubricating barrier on mucosal surfaces. This interaction promotes heterotypic cell adhesion and is suggested to play an important role in peritoneal metastasis of ovarian cancer. CA125 Protein, Human (Biotinylated, 685a.a, HEK293, His-Avi) is the recombinant human-derived CA125 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

Species: Human; Source: HEK293

CAR-T Related Proteins Biotinylated Proteins CA-125

/
HY-P78178 CA125 Protein, Human (Biotinylated, HEK293, His-Avi)
The CA125 protein acts by binding to MSLN and plays a crucial role in forming a protective and lubricating barrier on mucosal surfaces. This interaction promotes heterotypic cell adhesion and is suggested to play an important role in peritoneal metastasis of ovarian cancer. CA125 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived CA125 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

Species: Human; Source: HEK293

CAR-T Related Proteins Biotinylated Proteins CA-125

/
HY-P78370 Mesothelin Protein, Human (HEK293, His-Avi)
Mesothelin Protein, especially in its membrane-anchored forms, potentially mediates cellular adhesion, implicating its role in cell interactions. Furthermore, the associated Megakaryocyte-potentiating factor (MPF) actively enhances in vitro megakaryocyte colony formation, indicating its participation in fostering specialized blood cell colonies' development. Mesothelin Protein, Human (HEK293, His-Avi) is the recombinant human-derived Mesothelin protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

Species: Human; Source: HEK293

Receptor Proteins Cell Adhesion Molecules (CAMs)

/
HY-P78493 CA125 Protein, Human (HEK293, His-Avi)
The CA125 protein acts by binding to MSLN and plays a crucial role in forming a protective and lubricating barrier on mucosal surfaces. This interaction promotes heterotypic cell adhesion and is suggested to play an important role in peritoneal metastasis of ovarian cancer. CA125 Protein, Human (HEK293, His-Avi) is the recombinant human-derived CA125 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

Species: Human; Source: HEK293

CAR-T Related Proteins CA-125

/
HY-P78834 Mesothelin Protein, Mouse (Biotinylated, HEK293, His-Avi)
Mesothelin Protein, in its membrane-anchored forms, is implicated in cellular adhesion, suggesting a potential role in mediating cell interactions. Additionally, Megakaryocyte-potentiating factor (MPF) enhances megakaryocyte colony formation, indicating its involvement in the development of these specialized blood cell colonies. Mesothelin Protein, Mouse (Biotinylated, HEK293, His-Avi) is the recombinant mouse-derived Mesothelin protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of Mesothelin Protein, Mouse (Biotinylated, HEK293, His-Avi) is 303 a.a., with molecular weight of 45-60 kDa.

Species: Mouse; Source: HEK293

Receptor Proteins Cell Adhesion Molecules (CAMs)

/
HY-P78620 Mesothelin Protein, Rat (HEK293, His)
Mesothelin Protein, in its membrane-anchored forms, is implicated in cellular adhesion, suggesting a potential role in mediating cell interactions. Additionally, Megakaryocyte-potentiating factor (MPF) enhances megakaryocyte colony formation, indicating its involvement in the development of these specialized blood cell colonies. Mesothelin Protein, Rat (HEK293, His) is the recombinant rat-derived Mesothelin protein, expressed by HEK293 , with C-10*His labeled tag.

Species: Rat; Source: HEK293

Receptor Proteins Cell Adhesion Molecules (CAMs)

/
HY-P78644 FITC-Labeled Mesothelin Protein, Human (HEK293, His)
Mesothelin Protein, especially in its membrane-anchored forms, potentially mediates cellular adhesion, implicating its role in cell interactions. Furthermore, the associated Megakaryocyte-potentiating factor (MPF) actively enhances in vitro megakaryocyte colony formation, indicating its participation in fostering specialized blood cell colonies' development. FITC-Labeled Mesothelin Protein, Human (HEK293, His) is the recombinant human-derived FITC-Labeled Mesothelin protein, expressed by HEK293 , with C-His labeled tag.

Species: Human; Source: HEK293

Receptor Proteins Fluorescent-labeled Recombinant Proteins Cell Adhesion Molecules (CAMs)

/
HY-P72347 CA125 Protein, Human (Biotinylated, HEK293, Fc-Avi)
The CA125 protein acts by binding to MSLN and plays a crucial role in forming a protective and lubricating barrier on mucosal surfaces. This interaction promotes heterotypic cell adhesion and is suggested to play an important role in peritoneal metastasis of ovarian cancer. CA125 Protein, Human (Biotinylated, HEK293, Fc-Avi) is the recombinant human-derived CA125 protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag.

Species: Human; Source: HEK293

CAR-T Related Proteins Biotinylated Proteins CA-125

/
HY-P77797 Mesothelin Protein, Cynomolgus (Biotinylated, HEK293, His)
Mesothelin Protein, in its membrane-anchored forms, is implicated in cellular adhesion, suggesting a potential role in mediating cell interactions. Additionally, Megakaryocyte-potentiating factor (MPF) enhances megakaryocyte colony formation, indicating its involvement in the development of these specialized blood cell colonies. Mesothelin Protein, Cynomolgus (Biotinylated, HEK293, His) is the recombinant cynomolgus-derived Mesothelin protein, expressed by HEK293 , with C-His labeled tag.

Species: Cynomolgus; Source: HEK293

Receptor Proteins Biotinylated Proteins Cell Adhesion Molecules (CAMs)

/
HY-P78177 Mesothelin Protein, Mouse (Biotinylated, HEK293, His)
Mesothelin Protein, in its membrane-anchored forms, is implicated in cellular adhesion, suggesting a potential role in mediating cell interactions. Additionally, Megakaryocyte-potentiating factor (MPF) enhances megakaryocyte colony formation, indicating its involvement in the development of these specialized blood cell colonies. Mesothelin Protein, Mouse (Biotinylated, HEK293, His) is the recombinant mouse-derived Mesothelin protein, expressed by HEK293 , with C-His labeled tag.

Species: Mouse; Source: HEK293

Receptor Proteins Biotinylated Proteins Cell Adhesion Molecules (CAMs)

/
HY-P706207 CA125 Protein, Cynomolgus (HEK293, His)
The CA125 protein acts by binding to MSLN and plays a crucial role in forming a protective and lubricating barrier on mucosal surfaces. This interaction promotes heterotypic cell adhesion and is suggested to play an important role in peritoneal metastasis of ovarian cancer. CA125 Protein, Cynomolgus (HEK293, His) is the recombinant Cynomolgus-derived CA125 protein, expressed by HEK293 , with C-His labeled tag.

Species: Cynomolgus; Source: HEK293

CAR-T Related Proteins CA-125

/
HY-P703983 Mesothelin Protein, Human (112a.a, Biotinylated, HEK293, His, Avi)
Mesothelin Protein, especially in its membrane-anchored forms, potentially mediates cellular adhesion, implicating its role in cell interactions. Furthermore, the associated Megakaryocyte-potentiating factor (MPF) actively enhances in vitro megakaryocyte colony formation, indicating its participation in fostering specialized blood cell colonies' development. Mesothelin Protein, Human (112a.a, Biotinylated, HEK293, His, Avi) is the recombinant human-derived Mesothelin protein, expressed by HEK293, with C-Avi and C-His labeled tag.

Species: Human; Source: HEK293

Biotinylated Proteins

/
HY-P704787 Mesothelin Protein, Mouse (HEK293, Fc)
Mesothelin Protein, in its membrane-anchored forms, is implicated in cellular adhesion, suggesting a potential role in mediating cell interactions. Additionally, Megakaryocyte-potentiating factor (MPF) enhances megakaryocyte colony formation, indicating its involvement in the development of these specialized blood cell colonies. Mesothelin Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived Mesothelin protein, expressed by HEK293, with C-hFc labeled tag.

Species: Mouse; Source: HEK293

Receptor Proteins Cell Adhesion Molecules (CAMs)

/
HY-P704985 CA125 Protein, Human (Biotinylated, 642a.a, HEK293, Fc-Avi)
The CA125 protein acts by binding to MSLN and plays a crucial role in forming a protective and lubricating barrier on mucosal surfaces. This interaction promotes heterotypic cell adhesion and is suggested to play an important role in peritoneal metastasis of ovarian cancer. CA125, Human (Biotinylated, 642a.a, HEK293, Fc-Avi) is the recombinant human-derived CA125 protein, expressed by HEK293, with C-His labeled tag.

Species: Human; Source: HEK293

CAR-T Related Proteins Biotinylated Proteins CA-125

/
HY-P705174 CA125 Protein, Cynomolgus (Biotinylated, HEK293, His-Avi)

Species: Cynomolgus; Source: HEK293

CAR-T Related Proteins Biotinylated Proteins CA-125

/
HY-P705458 CA125 Protein, Human (642a.a, HEK293, His)
The CA125 protein acts by binding to MSLN and plays a crucial role in forming a protective and lubricating barrier on mucosal surfaces. This interaction promotes heterotypic cell adhesion and is suggested to play an important role in peritoneal metastasis of ovarian cancer. CA125, Human (642a.a, HEK293, His) is the recombinant human-derived CA125 protein, expressed by HEK293, with labeled tag.

Species: Human; Source: HEK293

CAR-T Related Proteins CA-125

/
HY-P81044 MUC16 Antibody (YA890)
MUC16 Antibody (YA890) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MUC16.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P81412 Mesothelin Antibody (YA1157)
Mesothelin Antibody (YA1157) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Mesothelin.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86790 BRCA2 Antibody (YA6483)
BRCA2 Antibody (YA6483) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to BRCA2.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P84539 Mesothelin Antibody (YA4236)
Mesothelin Antibody (YA4236) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Mesothelin.

Host: Mouse; Reactivity: Human, Monkey

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P86899 HEXB Antibody (YA6592)
HEXB Antibody (YA6592) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HEXB.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P84692 MUC16 Antibody (YA4389)
MUC16 Antibody (YA4389) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to MUC16.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P80991 MUC16 Antibody (YA3530)
MUC16 Antibody (YA3530) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MUC16.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81412A Mesothelin Antibody (YA1157)(PBS only)
Mesothelin Antibody (YA1157) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Mesothelin.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P84539A Mesothelin Antibody (YA4236)(PBS only)
Mesothelin Antibody (YA4236) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Mesothelin.

Host: Mouse; Reactivity: Human, Monkey

Monoclonal Antibodies Primary Antibodies

/
HY-P84540 Mesothelin Antibody (YA4237)
Mesothelin Antibody (YA4237) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Mesothelin.

Host: Mouse; Reactivity: Human, Rat

Monoclonal Antibodies Primary Antibodies

/
HY-P84540A Mesothelin Antibody (YA4237)(PBS only)
Mesothelin Antibody (YA4237) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Mesothelin.

Host: Mouse; Reactivity: Human, Rat

Monoclonal Antibodies Primary Antibodies

/
HY-P84692A MUC16 Antibody (YA4389)(PBS only)
MUC16 Antibody (YA4389) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to MUC16.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P85960 Mesothelin Antibody (YA5652)
Mesothelin Antibody (YA5652) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Mesothelin.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P86006 MUC16 Antibody (YA5698)
MUC16 Antibody (YA5698) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to MUC16.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P86753 MUC16 Antibody (YA6445)
MUC16 Antibody (YA6445) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to MUC16.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P86753A MUC16 Antibody (YA6445)(PBS only)
MUC16 Antibody (YA6445) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to MUC16.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P811100 SPIN1 Antibody
SPIN1 Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to SPIN1.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Primary Antibodies

/
HY-K2034 OptiLNP Antibody-ctLNP RNA Transfection Reagent (Human Primary T Cells)

MCE OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells) utilizes antibody-conjugated cell-targeted lipid nanoparticle (Cell-targeted Lipid Nanoparticle, ctLNP) technology and is specifically optimized for human primary T cells. It enables efficient and targeted RNA delivery, improving transfection efficiency in difficult-to-transfect primary T cells. The kit is ideally suited for applications including CAR-T and TCR-T cell engineering, cancer immunology research, immune cell engineering, and in vitro T cell functional studies.

Cell Biology Cell Culture Cell Transfection

/
HY-K6107 Human Cervical Cancer Organoid Kit

MCE Human Cervical cancer Organoid Kit contains Cervical cancer Organoid Basal Medium A, Cervical cancer Organoid Supplement B (50×), Cervical cancer Organoid Supplement C (250×). This product can be used to efficiently construct human cervical cancer organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6123 Human Ovarian Cancer Organoid Kit

MCE Human Ovarian Cancer Organoid Kit includes a basic culture medium for ovarian cancer organoids, as well as culture supplements, and is designed for the effective construction of human ovarian cancer organoids.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6123A Human Ovarian Cancer Organoid Complete Culture Medium

MCE Human Ovarian Cancer Organoid Complete Culture Medium is a pre-mixed, ready-to-use formulation composed of a basal ovarian cancer organoid medium and multiple key culture supplements at optimized ratios. This medium requires no additional preparation and enables the efficient and stable establishment of human ovarian cancer organoid models.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/

Keywords

CAR-T cells | gynecologic cancers | ovarian cancer | cervical cancer | MUC16 | mesothelin